Prothena Corporation had mixed results for Q4 2018. The company reported a loss of $0.56 per share, narrower than the Street's estimate loss of $0.96 cents and the year-ago loss of $1.24.
“In 2018, we continued to advance our neuroscience pipeline of novel investigational therapeutics towards key milestones,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. The company’s shares have lost 12.1% in the past six months compared with the industry's decline of 11.8%.